Month: September 2016

September 26, 2016
Elocta and Alprolix gain NHS reimbursement across the UK

21 September 2016 NHS England has confirmed reimbursement of Elocta® (efmoroctocog alfa) and Alprolix® (efrenonocog alfa) for the treatment of haemophilia A and B respectively. The decision means that Sobi’s recombinant factor VIII and IX Fc-fusion proteins with an extended half-life are now available across the UK. “We are really pleased to see the UK …

Read article